

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHANGE OF CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Director(s)**”) of China NT Pharma Group Limited (the “**Company**”) is pleased to announce that the following changes to the Chief Executive Officer (“**CEO**”) of the Company.

CHANGE OF CHIEF EXECUTIVE OFFICER

With the expansion of the Company’s scale of business and considering the development requirements of the Company, Mr. Ng Tit (“**Mr. Ng**”) wishes to dedicate more time to focus on matters such as developing strategies of the group. As such, Mr. Ng has resigned as the CEO with effect from 19 May 2025. Mr. Ng will remain as the Chairman of the Board and an executive Director. Mr. Ng and the Board confirmed that Mr. Ng has no disagreement with the Board and that neither of them is aware of any matter in relation to Mr. Ng’s resignation as the CEO that needs to be brought to the attention of the shareholders (“**Shareholders**”) of the Company.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Mr. Zhang Bozhi (張伯之) (“**Mr. Zhang**”), was appointed the CEO with effect from 19 May 2025.

The biographical details of Mr. Zhang are set out below:

Mr. Zhang, aged 45, is an experienced professional in the pharmaceutical industry, with several years of experience that spans various roles from sales representative to national sales director. Mr. Zhang has held positions in several well-known pharmaceutical companies including Sanofi China and Beijing Novartis. Mr. Zhang joined our Group since 2016, serving as Sales Manager, Sales Director, and other roles, and from August 2020 to April 2025, Mr. Zhang worked at our Associate company serving as Sales Director.

Mr. Zhang holds a Master's degree in Clinical Medicine from Tianjin Medical University. Apart from his successful corporate experiences, he has also worked as a resident physician at Tianjin People's Hospital. Mr. Zhang possesses excellent sales management, medical, and market experience in the pharmaceutical industry, along with outstanding team leadership skills. His keen industry insights enable him to develop excellent strategic plans that inject vitality into business development.

As at the date of this announcement, Mr. Zhang has confirmed that he does not (i) hold any other position in the Group nor have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (ii) hold any directorship in any other listed public companies and other major appointments and qualifications during the last three years preceding the date of this announcement; or (iii) have any interest in any shares, underlying shares or debentures of the Company or any of its associated corporations as defined under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, save as disclosed above, Mr. Zhang has confirmed that (i) there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; and (ii) there is no other information that needs to be brought to the attention of the shareholders of the Company in relation to his appointment.

The Board would like to express its warm welcome to Mr. Zhang on his new role as the CEO.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 19 May 2025

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Mr. Ng Ming Kwan.